RET

Applied Pharmaceutical Science RET Inhibitor IND Gets FDA Clearance

NICE Recommends Eli Lilly's Retsevmo for RET-Altered NSCLC Through Cancer Drugs Fund

European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC

UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund

Blueprint Medicines Q2 Revenues Increase More Than 200 Percent

Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors

AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting

Swiss Firm Helsinn Doses First Patient in Phase I/II Tumor-Agnostic RET Inhibitor Trial

Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC

COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials

FDA Approves Thermo Fisher Scientific CDx for Genentech's Gavreto in NSCLC Patients With RET Fusions

FDA Approves Blueprint Medicines, Genentech's Gavreto for RET-altered NSCLC

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers

FDA Approves Lilly's Retevmo for RET-Driven Lung, Thyroid Cancers

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications